CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 383 enrolled
Drug / intervention
LY3502970 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05048719
NCT05048719Phase 2Completed
CompareCT.gov

A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus

Eli Lilly and Company·interventional·Posted Sep 17, 2021·Updated Oct 17, 2023

In Brief

A Phase 2 clinical trial evaluating LY3502970, Dulaglutide, and 1 other intervention for Type 2 Diabetes. Completed, enrolled 383 participants across 44 sites in 5 countries.

Detailed Summary

The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesHungary, Poland, Puerto Rico, Slovakia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedSep 17, 2021
Enrollment StartSep 15, 2021
Primary CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 4.8 years ago

Interventions

LY3502970drug

Administered orally

Dulaglutidedrug

Administered subcutaneously

Placebodrug

Administered orally

Placebodrug

Administered subcutaneously